Search

What is RNA and how can we use the body's own RNA editing machinery to treat disease? Learn more about the Axiomer® RNA editing technology and how we are creating a new class of medicines.

Privacy Statement job applicants

ProQR has collaborations with important names in the industry including Eli Lilly and Company. Read more about our partnerships.

Download the latest ProQR corporate presentation (PDF).

ProQR Therapeutics - Shareholder meeting documents archive

Find out how RNA therapy works, how it differs from gene therapy and why we use it to treat genetic diseases that are currently untreatable.

Find out how ProQR’s stock is trading now and in the past. Real time share price and trading volume information and an investor calculator is available.

When our CEO, Daniel A. de Boer, knew his newborn son had an incurable rare disease, he founded ProQR to help people like his son. Learn more.

An innovative biotech company advancing our proprietary Axiomer RNA-editing platform technology.